Hepatic fibrosis and metabolic syndrome are more prevalent in PsA patients treated with methotrexate, compared to RA patients. Metabolic syndrome is associated with the risk of hepatic fibrosis in patients diagnosed with PsA and RA even after adjustment forcumulative methotrexate exposure.
Ratchaya Lertnawapan +3 more
wiley +1 more source
Histone lactylation: A key epigenetic modulator in the pathogenesis of metabolic dysfunction-associated steatohepatitis and alcoholic steatohepatitis. [PDF]
Singh MM +4 more
europepmc +1 more source
Effect of angiolin on the functional state of the liver in experimental steatohepatitis
K. V. Pivtorak
openalex +2 more sources
Organic solute transporter OSTα/β is overexpressed in nonalcoholic steatohepatitis and modulated by drugs associated with liver injury [PDF]
Melina M. Malinen +4 more
openalex +1 more source
Abstract Objective To assess the association between obstructive sleep apnea (OSA) risk levels and major cardiovascular disease (CVD) subtypes in individuals with metabolic dysfunction‐associated fatty liver disease (MAFLD). Methods This cohort study included 128,022 MAFLD participants from the UK Biobank without CVD at baseline.
Haizhen Chen +4 more
wiley +1 more source
Metabolic dysfunction-associated steatohepatitis is the leading indication for adult liver transplantation in Saudi Arabia. [PDF]
Alqahtani SA +7 more
europepmc +1 more source
Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease [PDF]
Brett McGettigan +7 more
openalex +1 more source
Modeling Steatohepatitis in Humans with Pluripotent Stem Cell-Derived Organoids.
Rie Ouchi +22 more
semanticscholar +1 more source
Imaging of Abdominal Complications in Children With Acute Lymphoblastic Leukaemia
ABSTRACT Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy and remains one of the most common causes of cancer‐related death in children and adolescents. Five‐year overall survival rates now exceed 90% with current multidrug chemotherapeutic regimens. This improvement, coupled with the toxicity of chemotherapy, has led to the
Luke R. Holmes +2 more
wiley +1 more source

